This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Clinical Study to Test How Effective and Safe GL...
Clinical trial

A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF) (PINTA)

Read time: 2 mins
Last updated:27th Sep 2018
Identifier: NCT03725852

This is a randomized, double-blind, parallel group, placebo-controlled, multicenter, exploratory Phase II study including subjects with Idiopathic Pulmonary Fibrosis (IPF), investigating GLPG1205 of top of local standard of care (defined as receiving nintedanib, pirfenidone, or neither nintedanib or pirfenidone).

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Randomized, Double-blind, Placebo-controlled, 26-week Study to Evaluate the Efficacy, Safety and Tolerability of GLPG1205 in Subjects With Idiopathic Pulmonary Fibrosis
Actual Study Start Date: September 27, 2018
Estimated Primary Completion Date: April 25, 2020
Estimated Study Completion Date: May 16, 2020

- Experimental:
GLPG1205 dose A
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2019-06-24
Study type(s) Interventional
Expected enrolment 60
Study start date 2018-09-27
Estimated primary completion date 2020-04-25

View full details